Zydus Lifesciences has informed that it enclosed a copy of press release dated December 15, 2023 titled ‘Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg, and tentative approval for 75 mg and 150 mg tablets.’
The above information is a part of company’s filings submitted to BSE.